Bart Frederick - Concepedia

Concepedia

Author

Bart Frederick

Janssen (United States)

Also Known As

B. Frederick, B.deS. Frederick, Bart Frederick

22

Publications

1.3K

Citations

14

H-Index

23

Concepts

All Affiliations

Janssen (United States)Springhouse Georgetown University Case Western Reserve University Kyoto University

BF

About

Bart Frederick is an author at Janssen (United States) specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	507
2	Pharmacology	5	5	232
3	Immunology	2	2	368
4	Biomedical Engineering	1	1	14
5	Clinical Immunology	1	1	275

Bart Frederick

×

16

Publications

1.3K

Citations

14

H-Index

	Year	Citations
A Phase I Study Evaluating the Safety, Pharmacokinetics, and Clinical Response of a Human IL-12 p40 Antibody in Subjects with Plaque Psoriasis Catharine Lisa Kauffman, Nancy Aria, Eiko Toichi, Journal of Investigative Dermatology Clinical ImmunologyMedicineImmunologyInflammatory MarkerPlaque Psoriasis	2004	275
An Anti-IL-12p40 Antibody Down-Regulates Type 1 Cytokines, Chemokines, and IL-12/IL-23 in Psoriasis Eiko Toichi, Gisela Torres, Thomas S. McCormick, The Journal of Immunology	2006	226
Abciximab Suppresses the Rise in Levels of Circulating Inflammatory Markers After Percutaneous Coronary Revascularization A. Michael Lincoff, Dean J. Kereiakes, Mary Ann Mascelli, Circulation	2001	196
A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis Alice B. Gottlieb, Kevin D. Cooper, Thomas S. McCormick, Current Medical Research and Opinion	2007	104
Pharmacokinetics, pharmacodynamics and safety of a human anti‐IL‐6 monoclonal antibody (sirukumab) in healthy subjects in a first‐in‐human study Zhenhua Xu, Esther Bouman‐Thio, Craig Comisar, British Journal of Clinical Pharmacology	2011	96
Subcutaneous Bioavailability of Golimumab at 3 Different Injection Sites in Healthy Subjects Zhenhua Xu, Qingmin Wang, Yanli Zhuang, The Journal of Clinical Pharmacology Healthy SubjectsSc GolimumabSubcutaneous BioavailabilityHematologyImmunology	2009	93
Golimumab Pharmacokinetics After Repeated Subcutaneous and Intravenous Administrations in Patients with Rheumatoid Arthritis and the Effect of Concomitant Methotrexate: An Open-Label, Randomized Study Yanli Zhuang, Zhenhua Xu, Bart Frederick, Clinical Therapeutics Rheumatoid DisorderRheumatologyMedicineRandomized StudyInflammatory Rheumatic Disease	2011	90
A Phase I, Single and Fractionated, Ascending‐Dose Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of an Erythropoietin Mimetic Antibody Fusion Protein (CNTO 528) in Healthy Male Subjects Esther Bouman‐Thio, Kari L. Franson, Bruce Miller, The Journal of Clinical Pharmacology	2008	41
Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial Mittie K. Doyle, Mahboob U. Rahman, Bart Frederick, Lara D. Veeken	2013	40
The first‐in‐human study of CNTO 7160, an anti‐interleukin‐33 receptor monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitis Ivo Nnane, Bart Frederick, Zhenling Yao, British Journal of Clinical Pharmacology	2020	36

Page 1